<DOC>
	<DOCNO>NCT02347891</DOCNO>
	<brief_summary>The goal trial evaluate efficacy safety belimumab maintenance therapy adult refractory Idiopathic inflammatory myositis ( IIM ) compare standard care . This multicentre double-blind , placebo-controlled trial .</brief_summary>
	<brief_title>Belimumab Myositis</brief_title>
	<detailed_description />
	<mesh_term>Myositis</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Subjects enrol study must meet follow inclusion criterion : 1 . Adults &gt; 18 year age 2 . Have diagnosis : 1. definite probable dermatomyositis ( DM ) 2 . Definite probable diagnosis polymyositis ( PM ) presence one myositis specific antibody . In absence myositis specific autoantibody , diagnosis PM require review muscle biopsy adjudication predetermine committee expert . 3 . Presence positive autoantibody ( ANA &gt; 1:80 RNP SSA/SSB myositis specific autoantibody : antisynthetase autoantibody ( antiJo1 , PL7 , PL12 , EJ , OJ , KS ) , antiSRP , antiMi2 , antip140 ) . 4 . Have refractory IIM define inadequate response intolerance least 3 month glucocorticoid and/or least one immunosuppressive agent , azathioprine , methotrexate , IVIG , mycophenolate mofetil , leflunomide , tacrolimus , cyclosporine cyclophosphamide , Rituximab . 5 . Have active IIM screening . This require least 3 criterion CSM 6 . Dermatomyositis patient meet MMT criterion , must : 1. cutaneous VAS score &gt; 3 cm 10 cm VAS scale ( MDAAT ) require : 2. elevation least one muscle enzyme ( creatine kinase [ CK ] ; aldolase ; lactate dehydrogenase [ LDH ] ; alanine aminotransferase [ ALT ] ; aspartate aminotransferase [ AST ] ) minimum level 1.3 time upper limit normal , 3. 1 additional core set measure 7 . For patient ≥ 7 year IIM , muscle biopsy muscle MRI within 4 month prior enrollment require document active myositis avoid enrol patient significant index damage/ muscle atrophy . This applicable DM patient cutaneous VAS score &gt; 3 cm 10 cm VAS scale ( MDAAT ) . 8 . Have stable background glucocorticoid therapy least 2 week prior screen ( Prednisone ( equivalent ) dose &lt; 15 mg daily ) 9 . Have stable immunosuppressive therapy ( IS ) ( azathioprine , mycophenolate mofetil , tacrolimus , cyclosporine &gt; 2 month prior screen . Patients intravenous gamma globulin ( IVIG ) stable dose frequency regimen ≥ 3 month . 10 . Have ability understand requirement study provide write informed consent ( include consent use disclosure researchrelated health information ) comply study protocol procedure ( include require study visit ) 11 . Female subject childbearing potential must negative urine pregnancy test screen agree 1 following : 1 . Complete abstinence intercourse 2 week prior administration 1st dose study agent 16 week last dose study agent ( Sexual inactivity abstinence must consistent preferred usual lifestyle subject . Periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception ) ; 2 . Consistent correct use 2 acceptable method birth control 1 month prior start study agent , study , 16 week last dose study agent Subjects meeting follow criterion exclude study : 1 . Have severe muscle damage define Muscle Damage Index ( MDI ) &gt; 5.0 cm use visual analogue scale ( VAS ) 10.0 cm length evidence severe muscle atrophy muscle MRI . 2 . History malignant neoplasm within last 5 year , except adequately treat cancer skin ( basal squamous cell ) . 3 . Have history primary immunodeficiency 4 . Have significant IgG deficiency ( IgG level &lt; 400 mg/dl ) Have IgA deficiency ( IgA level &lt; 10 mg/dL ) 5 . Discontinuation IS agent &lt; 3 month prior Screening . Including : azathioprine , methotrexate , mycophenolate mofetil , leflunomide , tacrolimus , cyclosporine , intravenous gamma globulin [ IVIG ] 6 . Have receive Rituximab within 365 day prior Screening . 7 . Have receive cyclophosphamide within 180 day prior Screening 8 . Have receive treatment : 1 . Initiated IVIG 3 month prior Screening 2 . Pulse steroids 2 month prior Screening 9 . Have receive treatment Belimumab time prior Screening 10 . Have receive biologic investigational agent within 365 day prior Screening . 11 . Have receive nonbiologic investigational agent within 30 day 5 halflives agent ( whichever longer ) prior Screening . 12 . Have history anaphylactic reaction parenteral administration contrast agent , human murine proteins monoclonal antibody . 13 . Infection history : 1 . Currently suppressive therapy chronic infection ( tuberculosis include latent tuberculosis , pneumocystis , cytomegalovirus , herpes simplex virus , herpes zoster atypical mycobacteria ) . NOTE : Testing latent TB standard care patient immunosuppressive therapy result obtain medical record . If TB history find patient , Quantiferon Gold PPD test perform prior Day 0 part standard care . 2 . Hospitalization treatment infection within 60 day Day 0 . 3 . Use parenteral ( IV IM ) antibiotic ( antibacterial , antiviral , antifungal , anti parasitic agent ) within 60 day Day 0 . 14 . Have historically positive HIV test test positive screening HIV . 15 . Have history autoimmune hepatitis 16 . Hepatitis status obtain patient ' medical record . If unavailable , test do part standard care . Patients exclude evidence infection : . Hepatitis B : . Positive hepatitis B surface antigen ( HBsAg ) positive hepatitis B core antibody ( HBcAb ) b . Hepatitis C : . Positive hepatitis C antibody confirmatory hepatitis C viral load PCR . 17 . Clinically significant elevation GGT ( &gt; 1.5xULN ) , bilirubin ( &gt; 1.25xULN , direct 35 % ) , INR ( &gt; 1.2 , exclude patient anticoagulant therapy ) clinically significant abnormal laboratory value opinion investigator . 18 . Have current drug alcohol abuse dependence , history drug alcohol abuse dependence within 364 day prior Day 0 . 19 . Have evidence serious suicide risk include history suicidal behaviour last 6 month and/or suicidal ideation last 2 month investigator 's judgment , pose significant suicide risk . 20 . Have concurrent significant medical psychiatric illness investigator considers would make candidate unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Inflammatory Myositis</keyword>
	<keyword>Dermatomyositis</keyword>
	<keyword>Polymyositis</keyword>
	<keyword>Muscle Pain</keyword>
	<keyword>Myositis</keyword>
	<keyword>Refractory myositis</keyword>
</DOC>